OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
H.I.G. Capital’s portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals.
H.I.G. Capital, a global alternative investment firm, announced on Oct. 3, 2022 that its portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals, a UK provider of niche generic and branded specialty pharmaceuticals. The financial terms of the transaction have not been disclosed.
Morningside is focused on developing and licensing niche generic pharmaceutical products, marketing over 160 stock keeping units across more than 80 product families and multiple therapeutic areas. According to a company press release, H.I.G. is combining Morningside with Aspire Pharma to build growth, product development, and support new initiatives, such as international expansion.
“We are excited to welcome the Morningside team to the Aspire family,” said Richard Condon, CEO of Aspire, in the release. “This is a transformative opportunity for both companies to expand and enhance our market position as a result of both companies highly complementary product portfolios. The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally.”
Source: H.I.G. Capital